

**Not for distribution, directly or indirectly,
in the United States of America, Australia, Canada or Japan**

MolMed: submitted the utilization request concerning the second tranche of the share capital increase to be reserved to Société Générale pursuant to “SEF – Standby Equity Facility” agreement

Milan, 7 August 2017 - MolMed S.p.A. (MLM.MI) (“**MolMed**” or the “**Company**”) announces to have submitted to Société Générale (“**SG**”) on 2 August 2017 an utilization request concerning the subscription of a second tranche (the “**Second Tranche**”) of the share capital increase without pre-emptive rights reserved to the same SG (the “**Share Capital Increase**”), resolved upon by the Board of Directors held on 15 November 2016 on the basis of the authorization granted to the Board of Directors by the Extraordinary Shareholders’ Meeting held on 7 November 2016, pursuant to the agreement named “SEF – Standby Equity Facility” executed on 6 October 2016 between the Company and SG (the “**SEF Agreement**”). The name “SEF – Standby Equity Facility” is an exclusive trade name of SG.

As already disclosed to the market, pursuant to the SEF Agreement SG has undertaken to subscribe the Share Capital Increase upon submission of discretionary requests from the Company (each, a “**Utilization Request**”) at the terms and conditions specified in the Agreement.

The subscription price of the Shares of the Second Tranche, equal to Euro 0.4089 per Share (of which Euro 0.0471 represents capital and the remainder represents share premium), has been determined in the three trading days following the submission of the relevant Utilization Request by MolMed (i.e., from 3 August 2017 to 7 August 2017 (included)), and is equal to 95% of the Volume Weighted Average Price (“**VWAP**”) of the ordinary shares of the Company as calculated over such period.

Pursuant to the SEF Agreement, with a notice dated as of today, SG has confirmed to subscribe for No. 4,500,000 ordinary shares of the Second Tranche, corresponding to the 1.03% of the share capital of MolMed, for an aggregate amount of Euro 1,840,050.

The execution of the SEF Agreement will enable the Company to find resources, by benefiting from the flexibility of such tool, to satisfy the Company’s periodic liquidity needs, as well as to contribute to the development of the industrial plans, over the term of 24 months of the SEF Agreement.

Pursuant to the SEF Agreement, SG is not subject to any lock-up on the Shares and the Company has not executed any agreement with SG for the resale of such Shares on the market. No stock lending agreement or guarantee on the Shares is in place between SG and the Company.

The Shares to be issued in relation to the Second Tranche, together with any ordinary shares issued in the 12 months preceding the date of the utilization request, do not exceed 10% of MolMed’s ordinary shares already admitted to trading on the Italian Stock Exchange on the date of the relevant Utilization Request and, therefore, the Second Tranche of the Share Capital Increase is exempt from the obligation to publish a listing prospectus, pursuant to Article 57, paragraph 1, let. a) of the regulation approved by CONSOB resolution no. 11971/1999.

The settlement of the aforementioned transaction is scheduled for 8 August 2017.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325

info@molmed.com - www.molmed.com

Share capital €20,312,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

This press release is written in compliance with public disclosure obligations established by Consob's (Italian securities & exchange commission) Issuers Regulation.

About MolMed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6 is an immune gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to market, including scale-up and cGMP manufacturing of viral vectors and patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).

For further information:

Laura Villa

Investor Relations & Communication Director

MolMed S.p.A.

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it

Andrea Quaglino

Administration, Finance & Control Director

MolMed S.p.A.

phone: +39 02 21277.302

fax: +39 02 21277.404

e-mail: afc@molmed.com